Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Olodaterol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 known ✓ | P07550 | 19/20 | 1.00 |
| ▸ | ADRB1 | P08588 | 17/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 1/20 | 1.00 |
| ▸ | HTR1A | P08908 | 1/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 1/20 | 1.00 |
| ▸ | HTR2A | P28223 | 1/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 1/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 1/20 | 1.00 |
| ▸ | PTGS2 | P35354 | 1/20 | 1.00 |
| ▸ | HTR2B | P41595 | 1/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 1.00 |
| ▸ | PDE4D | Q08499 | 1/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Olodaterol SCHEMBL29737213 | 1.00 | ADRB2 (1.00) | ADRB2ADRB1CHRM2HTR1AADRA2A | |
| Olodaterol SCHEMBL29355155 | 1.00 | ADRB2 (1.00) | ADRB2ADRB1CHRM2HTR1AADRA2A | |
| Olodaterol SCHEMBL560926 | 1.00 | ADRB2 (1.00) | ADRB2ADRB1CHRM2HTR1AADRA2A | |
| Olodaterol SCHEMBL29371816 | 0.99 | ADRB1 (1.00) | ADRB2ADRB1CHRM2HTR1AADRA2A | |
| Olodaterol SCHEMBL152331 | 0.99 | ADRB1 (1.00) | ADRB2ADRB1CHRM2HTR1AADRA2A | |
| Olodaterol SCHEMBL560669 | 0.99 | ADRB1 (1.00) | ADRB2ADRB1CHRM2HTR1AADRA2A | |
| Olodaterol SCHEMBL561592 | 0.95 | ADRB2 (0.90) | ADRB2ADRB1CHRM2HTR1AADRA2A | |
| Olodaterol SCHEMBL561364 | 0.94 | ADRB2 (0.89) | ADRB2ADRB1CHRM2HTR1AADRA2A | |
| Olodaterol SCHEMBL560886 | 0.94 | ADRB2 (0.89) | ADRB2ADRB1CHRM2HTR1AADRA2A | |
| Olodaterol SCHEMBL4219120 | 0.94 | ADRB2 (0.89) | ADRB2ADRB1CHRM2HTR1AADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 655 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2422786-B1 | New medicine combinations for treating respiratory diseases | BOEHRINGER INGELHEIM PHARMA (DE) | 2014-08-13 | — | — | EP | claimed |
| EP-2422786-A1 | New medicine combinations for treating respiratory diseases | Boehringer Ingelheim Pharma GmbH & Co. KG (DE) | 2012-02-29 | — | — | EP | claimed |
| EP-1781298-B1 | PHARMACEUTICAL COMBINATIONS CONTAINING BENZOXAZINE FOR TREATING RESPIRATORY DISEASES | BOEHRINGER INGELHEIM INT (DE) | 2012-01-04 | — | — | EP | claimed |
| EP-1940409-B1 | NOVEL PHARMACEUTICAL COMBINATIONS FOR THE TREATMENT OF RESPIRATORY DISORDERS | BOEHRINGER INGELHEIM INT (DE) | 2010-09-29 | — | — | EP | claimed |
| US-20090181961-A1 | NOVEL MEDICAMENTS FOR THE TREATMENT OF RESPIRATORY DISEASES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-07-16 | — | — | US | claimed |
| US-7056916-B2 | Medicaments for the treatment of chronic obstructive pulmonary disease | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2006-06-06 | — | — | US | claimed |
| US-20060106213-A1 | New Medicaments for the Treatment of Chronic Obstructive Pulmonary Disease | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2006-05-18 | — | — | US | claimed |
| US-20040147513-A1 | New medicaments for the treatment of chronic obstructive pulmonary disease | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-07-29 | — | — | US | claimed |
| US-20250205232-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-06-26 | — | — | US | disclosed |
| EP-2152341-B2 | ATOMIZER IN THE FORM OF AN INHALER FOR MEDICAL AEROSOL THERAPY | BOEHRINGER INGELHEIM PHARMA (DE) | 2025-04-02 | — | — | EP | disclosed |
| US-12209094-B2 | CCR2 receptor antagonists and uses thereof | CENTREXION THERAPEUTICS CORPORATION (US) | 2025-01-28 | — | — | US | disclosed |
| US-12168009-B2 | Modulators of cystic fibrosis transmembrane conductance regulator | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2024-12-17 | — | — | US | disclosed |
| US-11951212-B2 | Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2024-04-09 | — | — | US | disclosed |
| US-20240109909-A1 | CCR2 RECEPTOR ANTAGONISTS AND USES THEREOF | ANKURA TRUST COMPANY, LLC, AS ADMINISTRATIVE AND COLLATERAL AGENT | 2024-04-04 | — | — | US | disclosed |
| WO-2005102349-A1 | PHARMACEUTICAL COMBINATIONS CONTAINING BENZOXAZINE FOR TREATING RESPIRATORY DISEASES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-11-03 | — | — | WO | disclosed |
| US-20050239778-A1 | Novel medicament combinations for the treatment of respiratory diseases | BOEHRINGER INGELHEIM INTERNATIONAL GMBH | 2005-10-27 | — | — | US | disclosed |
| US-20050222144-A1 | Medicaments for the treatment of chronic obstructive pulmonary disease | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2005-10-06 | — | — | US | disclosed |
| EP-1562603-A2 | NOVEL MEDICAMENTS FOR THE TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASES | Boehringer Ingelheim Pharma GmbH & Co.KG (DE) | 2005-08-17 | — | — | EP | disclosed |
| US-20040147513-A1 | New medicaments for the treatment of chronic obstructive pulmonary disease | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-07-29 | — | — | US | disclosed |
| WO-2004045618-A2 | NOVEL MEDICAMENTS FOR THE TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASES | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-06-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060106213-A1 | New Medicaments for the Treatment of Chronic Obstructive Pulmonary Disease | SLC26A4, CHRM1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | ADRB2 50/4885ADRB1 69/4885CHRM2 6/4885 |
| US-20090181961-A1 | NOVEL MEDICAMENTS FOR THE TREATMENT OF RESPIRATORY DISEASES | MRGPRX2, MRGPRX1, CFTR | ADRB2 49/4885ADRB1 115/4885CHRM2 13/4885 |
| US-20250205232-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1B, SLC26A4 | ADRB2 522/4885ADRB1 308/4885CHRM2 220/4885 |
| US-20050222144-A1 | Medicaments for the treatment of chronic obstructive pulmonary disease | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, SLC26A4, CHRM1 | ADRB2 27/4885ADRB1 38/4885CHRM2 5/4885 |
| US-20040147513-A1 | New medicaments for the treatment of chronic obstructive pulmonary disease | CLIC1, OTC, SLC10A1 | ADRB2 80/4885ADRB1 56/4885CHRM2 85/4885 |
| US-20050239778-A1 | Novel medicament combinations for the treatment of respiratory diseases | MRGPRX2, MRGPRX1, MTNR1B | ADRB2 11/4885ADRB1 73/4885CHRM2 10/4885 |
| US-20240109909-A1 | CCR2 RECEPTOR ANTAGONISTS AND USES THEREOF | CCR2, CCRL2, CCR1 | ADRB2 55/4885ADRB1 90/4885CHRM2 166/4885 |
| US-12168009-B2 | Modulators of cystic fibrosis transmembrane conductance regulator | CFTR, SCNN1B, SLC26A4 | ADRB2 522/4885ADRB1 308/4885CHRM2 220/4885 |
| US-11951212-B2 | Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases | CFTR, SLC26A4, PKD1 | ADRB2 1836/4885ADRB1 1307/4885CHRM2 971/4885 |
| US-12209094-B2 | CCR2 receptor antagonists and uses thereof | CCR2, CCRL2, CCR1 | ADRB2 55/4885ADRB1 90/4885CHRM2 166/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.